Markets

Sun Pharmaceutical To Buy Organon For $11.75 Bln

April 27, 2026 — 03:11 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Sun Pharmaceutical Industries Limited (SUNPHARMA, 524715), a major Indian pharma company, said on Monday that it has inked a deal to buy Organon & Co.(OGN) for $14 per share in cash with an enterprise value of $11.75 billion.

Kirti Ganorkar, Managing Director of Sun Pharma, said: "This transaction is a logical next step in strengthening Sun Pharma's global business. Together, we will become a partner of choice for acquiring and launching new products. We see strong potential in leveraging Organon's talent pool. In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."

Sun Pharma plans to fund the acquisition, expected to be closed in early 2027, through cash on hand and debt. Post transaction, Sun Pharmaceutical is expected to report a combined revenue of $12.4 billion.

For fiscal 2025, Organon had reported adjusted EBITDA of $1.9 billion, with revenue of $6.2 billion.

SUNPHARMA was up by 7.17% at Rs 1736.60 on the National Stock Exchange.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
OGN

Latest Articles
Data is currently not available